SEP 14, 2020 2:46 PM PDT

MiR-107 and Its Role in Radiosensitivity in Prostate Cancer

WRITTEN BY: Jasper Cantrell

It is often unknown whether a patient will respond to a treatment until it is in full swing. New research is attempting to identify chemo and radiosensitivity mechanisms in cancers and how to use them to reverse resistances.

An area of keen interest is microRNAs and their role in cancer. MicroRNAs (miRNAs) are small snippets of RNA that regulate many processes in the cell. During the development of cancer, their levels fluctuate and can become inactive or overactive. This new study wanted to focus on one miRNA in particular, miR-107, and its effect on prostate cancer’s radiosensitivity.

Previous studies had already shown that miR-107 becomes downregulated after radiation therapy. A link between miR-107 and a pro-cancer growth factor called granulin had previously been identified, but not in the context of radiation therapy. The team hypothesized that both miR-107 and granulin might play a role in the radiosensitivity of prostate cancer.

They first confirmed that miR-107 was downregulated after radiotherapy by following its prostate cancer cell line levels before and after radiation. Artificially upregulating miR-107 impaired prostate cancer cells’ growth after radiation, inferring miR-107 has tumor suppressor activities.

Next, the team looked at granulin levels in the same settings. A previous study and several prediction tools showed the miR-107 should target and regulate granulin expression. Granulin was also upregulated in prostate cancer cells after radiation, in contrast to the downregulation in miR-107. When miR-107 was artificially upregulated, granulin levels went down in response, which effectively showed miR-107 likely regulated granulin in prostate cancer cells. The anti-cancer effects seen in miR-107 upregulation were also found to be due to its regulation of granulin, as knockdown of granulin caused the same results.

This study successfully revealed miR-107 as a player in the radio-sensitivity of prostate cancer cells through its regulation of granulin. Granulin has been linked to cancer progression in several previous studies and is upregulated after prostate cancer radiation. Artificial upregulation of miR-107 suppresses granulin levels and impairs cancer growth. One could imagine a miR-107 upregulating therapy alongside radiotherapy for maximum effectiveness.

The study concludes, “Collectively, these data suggest an unrecognized mechanism of miR-107/ GRN regulation in response to ionizing radiation, which provide a potential therapeutic strategy for improving radiosensitivity of prostate cancer.”

Sources: Nature Scientific Reports, Memorial Sloan Kettering

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUN 16, 2021
Cancer
New drug attacks pancreatic tumors with mutant KRAS addiction
JUN 16, 2021
New drug attacks pancreatic tumors with mutant KRAS addiction
Pancreatic cancer is notoriously difficult to detect in early stages, which is why it is associated with a low survival ...
JUL 23, 2021
Cancer
Repurposed Antibiotics Show Promise Against Skin Cancer
JUL 23, 2021
Repurposed Antibiotics Show Promise Against Skin Cancer
In experiments with mice, researchers from the Netherlands have found that some antibiotics may be effective in tre ...
AUG 07, 2021
Cancer
New Drug Combo Eliminates Pancreatic Cancer in Mice
AUG 07, 2021
New Drug Combo Eliminates Pancreatic Cancer in Mice
A combination of three immunotherapy drugs can eliminate pancreatic tumors in mice. The study was published in Canc ...
AUG 18, 2021
Cannabis Sciences
Cancer Patients Use Less Cannabis than General Public
AUG 18, 2021
Cancer Patients Use Less Cannabis than General Public
Despite increasing legalization for recreational cannabis across the US, cancer patients have largely abstained from usi ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
Loading Comments...